BridgeBio Pharma's experimental drug Infigratinib accelerates growth in height for achondroplasia patients, increasing annualized height velocity by 2.5 cm after 18 months.
BridgeBio Pharma's experimental drug has shown promising results in accelerating growth in height for a dozen people with achondroplasia, the most common cause of disproportionate short stature. Infigratinib, the drug in question, increased annualized height velocity by 2.5 cm after 18 months compared to baseline. Treatment also improved body proportionality. The biotech company has completed a Phase 2 study and plans to complete enrollment for a Phase 3 study by the end of the year.
June 04, 2024
3 Articles